11.41
-0.76(-6.24%)
Currency In USD
| Previous Close | 12.17 |
| Open | 12.02 |
| Day High | 12.4 |
| Day Low | 11.41 |
| 52-Week High | 13.29 |
| 52-Week Low | 2.69 |
| Volume | 106,205 |
| Average Volume | 43,901 |
| Market Cap | 264.9M |
| PE | -3.88 |
| EPS | -2.94 |
| Moving Average 50 Days | 10.78 |
| Moving Average 200 Days | 8.63 |
| Change | -0.76 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $3.11 as of December 21, 2024 at a share price of $11.41. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $101.35 as of December 21, 2024 at a share price of $11.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silenc
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
GlobeNewswire Inc.
Nov 14, 2024 9:30 PM GMT
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
GlobeNewswire Inc.
Nov 04, 2024 1:00 PM GMT
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silenc